E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal Article
Magnesium in acute myocardial infarction: still an open question.
TL;DR: It was concluded that magnesium has no place in treatment of AMI, and administration of high dose magnesium with an angiotensin-converting enzyme inhibitor or the vasodilating oral nitrate in arms of ISIS-4 may have contributed to adverse effects of hypermagnesemia.
Journal ArticleDOI
Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
TL;DR: The clinical superiority of enoxaparin versus unfractionated heparin (UFH) depends on a more stable antithrombotic effect or the proportion of patients not reaching the therapeutic level with UFH has not been addressed.
Journal ArticleDOI
Clinical Practice Guidelines on Perioperative Cardiovascular Evaluation: Collaborative Efforts Among the ACC, AHA, and ESC
Jeffrey L. Anderson,Elliott M. Antman,John Gordon Harold,Mariell Jessup,Patrick T. O'Gara,Fausto J. Pinto,Panos E. Vardas,José Luis Zamorano +7 more
TL;DR: 2 new versions of clinical practice guidelines (CPGs) on perioperative cardiovascular evaluation from the American College of Cardiology, the American Heart Association, and the European Society of cardiology are announced.
Journal ArticleDOI
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial
Bram J. Geller,Robert P. Giugliano,Eugene Braunwald,Sabina A. Murphy,James J. Hanyok,Jianqing Jin,Michele Mercuri,Elliott M. Antman,Christian T. Ruff +8 more
TL;DR: In this paper, the authors performed a prespecified analysis in 21,105 patients with AF enrolled in the ENGAGE AF-TIMI 48 trial, which compared two once-daily regimens of edoxaban with warfarin for the prevention of stroke and systemic embolic events (SEEs).
Journal ArticleDOI
The 50th anniversary of the US surgeon general's report on tobacco: what we've accomplished and where we go from here.
TL;DR: January 11, 2014, marks the 50th anniversary of a significant milestone in the authors' nation's public health, when the first Surgeon General's Report on Smoking and Health was released.